Omeros Co. (NASDAQ:OMER)’s stock price rose 5.6% during trading on Monday . The company traded as high as $12.30 and last traded at $12.26. Approximately 1,680,091 shares changed hands during trading, an increase of 83% from the average daily volume of 918,302 shares. The stock had previously closed at $11.61.

A number of brokerages recently weighed in on OMER. Wedbush decreased their price objective on shares of Omeros from $17.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, September 1st. Zacks Investment Research upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Thursday, September 3rd. BidaskClub raised shares of Omeros from a “strong sell” rating to a “sell” rating in a research report on Friday, September 11th. Maxim Group lowered their price target on shares of Omeros from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, HC Wainwright dropped their price objective on Omeros from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, August 21st. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $19.75.

The firm’s 50-day moving average price is $12.71 and its 200-day moving average price is $13.96. The stock has a market capitalization of $668.94 million, a PE ratio of -6.24 and a beta of 1.66.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.02). The business had revenue of $13.53 million during the quarter, compared to the consensus estimate of $18.12 million. On average, equities research analysts expect that Omeros Co. will post -1.82 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Omeros by 90.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,085 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,843 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Omeros during the 2nd quarter worth about $328,000. State Street Corp grew its holdings in Omeros by 4.9% in the first quarter. State Street Corp now owns 1,161,905 shares of the biopharmaceutical company’s stock valued at $15,535,000 after purchasing an additional 53,885 shares during the period. Nuveen Asset Management LLC lifted its holdings in Omeros by 10.9% during the first quarter. Nuveen Asset Management LLC now owns 221,640 shares of the biopharmaceutical company’s stock valued at $2,963,000 after purchasing an additional 21,821 shares in the last quarter. Finally, Balyasny Asset Management LLC purchased a new stake in Omeros during the 1st quarter worth approximately $434,000. Institutional investors own 58.36% of the company’s stock.

About Omeros (NASDAQ:OMER)

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: What are the risks of holding treasury bonds?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.